Cervarix adverse reactions a hot topic in MHRA's latest safety update
This article was originally published in Scrip
While the UK MHRAencourages people to report suspected adverse reactions to GlaxoSmithKline's Cervarix now that the routine immunisation programme for human papillomavirus has started, it advises that caution should be exercised in reporting reactions associated with the injection process.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.